We use cookies on our website. Carry on browsing if you’re happy with this or find out more


Anti-ICOS monoclonal antibody

Advanced solid tumours, Phase 1/2

KY1044 page image

KY1044 is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. KY1044 is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells.

KY1044 can also improve the ratio of intra-tumoral effector T cells to regulatory T cells which promotes an anti-tumour immune response. In preclinical studies, we have demonstrated that KY1044 can promote a significant and long-lasting anti-tumour effect as monotherapy or as a synergistic combination with anti-PD-L1. We are currently conducting a Phase 1/2 clinical trial of KY1044 in patients with advanced solid tumours as a monotherapy and in combination with atezolizumab. We expect initial safety and activity data from the monotherapy and the combination trial in 2020.

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline